189 related articles for article (PubMed ID: 32579346)
1. Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity.
Panyain N; Godinat A; Lanyon-Hogg T; Lachiondo-Ortega S; Will EJ; Soudy C; Mondal M; Mason K; Elkhalifa S; Smith LM; Harrigan JA; Tate EW
J Am Chem Soc; 2020 Jul; 142(28):12020-12026. PubMed ID: 32579346
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin C-Terminal Hydrolase L1: Biochemical and Cellular Characterization of a Covalent Cyanopyrrolidine-Based Inhibitor.
Krabill AD; Chen H; Hussain S; Feng C; Abdullah A; Das C; Aryal UK; Post CB; Wendt MK; Galardy PJ; Flaherty DP
Chembiochem; 2020 Mar; 21(5):712-722. PubMed ID: 31449350
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule Activity-Based Probe for Monitoring Ubiquitin C-Terminal Hydrolase L1 (UCHL1) Activity in Live Cells and Zebrafish Embryos.
Kooij R; Liu S; Sapmaz A; Xin BT; Janssen GMC; van Veelen PA; Ovaa H; Dijke PT; Geurink PP
J Am Chem Soc; 2020 Sep; 142(39):16825-16841. PubMed ID: 32886496
[TBL] [Abstract][Full Text] [Related]
4. Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1.
Krabill AD; Chen H; Hussain S; Hewitt CS; Imhoff RD; Muli CS; Das C; Galardy PJ; Wendt MK; Flaherty DP
Molecules; 2021 Feb; 26(5):. PubMed ID: 33668938
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
[TBL] [Abstract][Full Text] [Related]
6. Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1.
Imhoff RD; Patel R; Safdar MH; Jones HBL; Pinto-Fernandez A; Vendrell I; Chen H; Muli CS; Krabill AD; Kessler BM; Wendt MK; Das C; Flaherty DP
J Med Chem; 2024 Mar; 67(6):4496-4524. PubMed ID: 38488146
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin carboxy-terminal hydrolase L1 - physiology and pathology.
Matuszczak E; Tylicka M; Komarowska MD; Debek W; Hermanowicz A
Cell Biochem Funct; 2020 Jul; 38(5):533-540. PubMed ID: 32207552
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin C-terminal hydrolase L1 is required for pancreatic beta cell survival and function in lipotoxic conditions.
Chu KY; Li H; Wada K; Johnson JD
Diabetologia; 2012 Jan; 55(1):128-40. PubMed ID: 22038515
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver disease.
Wilson CL; Murphy LB; Leslie J; Kendrick S; French J; Fox CR; Sheerin NS; Fisher A; Robinson JH; Tiniakos DG; Gray DA; Oakley F; Mann DA
J Hepatol; 2015 Dec; 63(6):1421-8. PubMed ID: 26264933
[TBL] [Abstract][Full Text] [Related]
10. UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology.
Mondal M; Conole D; Nautiyal J; Tate EW
Br J Cancer; 2022 Jan; 126(1):24-33. PubMed ID: 34497382
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin C-Terminal Hydrolase L1 regulates autophagy by inhibiting autophagosome formation through its deubiquitinating enzyme activity.
Yan C; Huo H; Yang C; Zhang T; Chu Y; Liu Y
Biochem Biophys Res Commun; 2018 Mar; 497(2):726-733. PubMed ID: 29462615
[TBL] [Abstract][Full Text] [Related]
12. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK).
Davies CW; Chaney J; Korbel G; Ringe D; Petsko GA; Ploegh H; Das C
Bioorg Med Chem Lett; 2012 Jun; 22(12):3900-4. PubMed ID: 22617491
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin C-terminal hydrolase L1 (UCHL1) regulates post-myocardial infarction cardiac fibrosis through glucose-regulated protein of 78 kDa (GRP78).
Lei Q; Yi T; Li H; Yan Z; Lv Z; Li G; Wang Y
Sci Rep; 2020 Jun; 10(1):10604. PubMed ID: 32606430
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of UCHL1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target.
Powis RA; Mutsaers CA; Wishart TM; Hunter G; Wirth B; Gillingwater TH
Neuropathol Appl Neurobiol; 2014 Dec; 40(7):873-87. PubMed ID: 25041530
[TBL] [Abstract][Full Text] [Related]
15. UCH-L3 structure and function: Insights about a promising drug target.
Hafez N; Modather El-Awadly Z; Arafa RK
Eur J Med Chem; 2022 Jan; 227():113970. PubMed ID: 34752952
[TBL] [Abstract][Full Text] [Related]
16. Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1.
Zhang M; Deng Y; Luo Y; Zhang S; Zou H; Cai F; Wada K; Song W
J Neurochem; 2012 Mar; 120(6):1129-38. PubMed ID: 22212137
[TBL] [Abstract][Full Text] [Related]
17. Role of ubiquitin C-terminal hydrolase-L1 in antipolyspermy defense of mammalian oocytes.
Susor A; Liskova L; Toralova T; Pavlok A; Pivonkova K; Karabinova P; Lopatarova M; Sutovsky P; Kubelka M
Biol Reprod; 2010 Jun; 82(6):1151-61. PubMed ID: 20164442
[TBL] [Abstract][Full Text] [Related]
18. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
[TBL] [Abstract][Full Text] [Related]
19. Correction to "Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity".
Panyain N; Godinat A; Lanyon-Hogg T; Lachiondo-Ortega S; Will EJ; Soudy C; Mondal M; Mason K; Elkhalifa S; Smith LM; Harrigan JA; Tate EW
J Am Chem Soc; 2020 Sep; 142(35):15199. PubMed ID: 32812749
[No Abstract] [Full Text] [Related]
20. The emerging role of deubiquitylating enzyme USP21 as a potential therapeutic target in cancer.
Shi ZY; Li CY; Chen RY; Shi JJ; Liu YJ; Lu JF; Yang GJ; Chen J
Bioorg Chem; 2024 Jun; 147():107400. PubMed ID: 38688196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
